-
Mashup Score: 0Ovarian cancer symptoms, risks, and prevention: HealthLink - 2 year(s) ago
Ovarian cancer is serious because it is often found in its later stages. It’s why doctors and survivors urge women to know the warning signs.
Source: king5.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing - PubMed - 2 year(s) ago
Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We describe a remarkable response to targeted therapy in a patient with platinum-resistant, advanced LGSOC who had failed standard-of-care chemotherapy …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing https://t.co/N08LpdrM0b organoid directed drug testing performed by @SEngineMedicine directed tx literally rescued a #LGSOC pt from the brink of death!👇🚨 #lowgradeserous https://t.co/06MfFcIl7Y
-
-
Mashup Score: 1Any Mountain Everest - 2 year(s) ago
Event Home Donate Register Sponsors Merchandise …
Source: Any Mountain EverestCategories: Hem/Oncs, Latest HeadlinesTweet-
For a word without ovarian cancer…. First ovarian cancer survivor in history summits Mt Everest! Congratulations @Jess.Wedel and @anymountainsong! #jointheclimb #anymountaineverest #anymountainsong Donate: https://t.co/Ftp6Zw6qiC Website: https://t.co/8K9z5m2JJy https://t.co/bHnDlEz7fV
-
-
Mashup Score: 0
This cohort study compares the management and outcomes of patients with early pregnancy loss who present to the emergency department vs outpatient clinics.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Early Pregnancy Loss Management in the Emergency Department vs Outpatient Setting https://t.co/dQyVY5wrMp via @JAMANetworkOpen part of @JAMANetwork Great work by @UWashOBGYN @UWMedicine faculty Lyndsey Benson and mentors @gorejohn @LisaCallegari
-
-
Mashup Score: 1
When are we going to get more serious about the highest-security labs?
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrBenNeel: A reasonable and reasoned take on an important issue https://t.co/wie3ddRaNj
-
-
Mashup Score: 0SGO Journal Club: Dear Healthcare Provider… the Changing Landscape of PARP Inhibitor Indications | SGO ConnectEd - 2 year(s) ago
Since 2014, the FDA has approved use of PARP inhibitors for treatment of ovarian cancer in various clinical contexts including as monotherapy for recurrent ovarian cancer, as maintenance therapy after response to platinum-based chemotherapy in recurrent ovarian cancer, and as maintenance therapy after response to upfront platinum-based chemotherapy. However, in 2022, the FDA sent out a series of…
Source: connected.sgo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
SGO Journal Club: Dear Healthcare Provider… the Changing Landscape of PARP Inhibitor Indications https://t.co/rPy7V8OduM https://t.co/VUeTKqZ8jF
-
-
Mashup Score: 0
This GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritize …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line … https://t.co/OoxUqIkTh2 practice changing publication 🚨! 👀👇🧵 1/7
-
-
Mashup Score: 0CA-125 - Biomarker Kinetics™ - 2 year(s) ago
Modeled CA-125 KELIM™ in patients with stage III-IV high grade serous ovarian carcinomas treated with first line adjuvant chemotherapy
Source: www.biomarker-kinetics.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
6/7 best of all: there is a free and easy to use online KELIM calculator that works for primary debulking or neoadjuvant chemo: https://t.co/WUNZPkf0Us
-
-
Mashup Score: 0Layout - 2 year(s) ago
FWC Move 4 Her 2022 : Make a donation today to support FWC Move 4 Her 2022
Source: move4her.raisely.comCategories: Hem/Oncs, Latest HeadlinesTweet-
It is Gynecologic Awareness Month. Spread the word! FWC Move 4 Her 2022 : Make a donation today to support FWC Move 4 Her 2022 https://t.co/iWiLoDw5UP #fwc-move-4-her-2022 via @raisely https://t.co/CWuytdTCSP
-
-
Mashup Score: 0
Clovis Oncology, US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundation Translational Award.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
I get asked a lot about testing for HRD in ovarian cancers to inform use of PARP inhibition. When there is more than 1 pathology specimen, which one should you test? Good question! We have data from ARIEL2 (https://t.co/FHjHbl5ldK) to help us. See 🧵👇 for explanation. 1/5 https://t.co/hcFnzb66h5
-
Thank you @KING5Seattle for this important message! @ocrahope @MNOvarianCancer @anymountainsong Ovarian cancer symptoms, risks, and prevention: HealthLink https://t.co/BZIqytpsN2 via @KING5Seattle